PACAP 6-38 acetate

Catalog No.S8416 Batch:S841601

Print

Technical Data

Formula

C182H300N56O45S
Molecular Weight 4083.74 CAS No. 143748-18-9(free base)
Solubility (25°C)* In vitro Water 100 mg/mL (24.48 mM)
 
 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PACAP 6-38 acetate is a PACAP (pituitary adenylate cyclase-activating polypeptide) non-stimulating competitive antagonist with an IC50 value of 2 nM. It also acts as a functional CARTp antagonist in vivo.
Targets
CARTp [2] PACAP receptor [1]
2 nM
In vitro

PACAP 6-38 blocks the CARTp-induced phosphorylation of ERK in differentiated cells[2].
In vivo

Intravesical administration of the PAC1 receptor antagonist, PACAP(6-38) (300 nM), significantly (p ≤ 0.01) increases intercontraction interval (2.0-fold) and void volume (2.5-fold) in NGF-OE mice. PACAP(6-38) has no effects on bladder function in WT mice. Intravesical administration of PACAP(6–38) (300 nM) significantly (p ≤ 0.01) reduces pelvic sensitivity in NGF-OE mice but is without effect in WT mice[4].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    SK-N-MC neuroblastoma cells

  • Concentrations

    30 μM

  • Incubation Time

    4 h

  • Method

    Cells are incubated for 4 h with 300 nM PACAP-38 in the absence or presence of the PACAP antagonist PACAP (6-38), medium is collected, and proteins are separated by SDS/PAGE and blotted onto PVDF membranes. For APPsα detection, membranes are probed with the antibody 6E10 followed by an anti-mouse antibody labeled with HRP, detection is performed with the ECL plus system.
Animal Study:

[2]
  • Animal Models

    Male Sprague-Dawley rats

  • Dosages

    0.3 nmol, 0.6 nmol, 3 nmol (1.5 Μl/340g)

  • Administration

    i.c.v

Selleck's PACAP 6-38 acetate has been cited by 1 publication

PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy [ Front Immunol, 2021, 12:714244] PubMed: 34552585

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.